John Waddell - Experiences with the subclinical control of PCV2

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Notes on slide 1

    To print as a PDF: Select Select the Acrobat Distiller as the printer name Print/save to a location where you can find the file back.

    Favorites, Groups & Events

    John Waddell - Experiences with the subclinical control of PCV2 - Presentation Transcript

    1. FIELD EVALUATION OF INGELVAC CIRCOFLEX ® ON GROWTH PERFORMANCE OF PIGS IN A SUBCLINICAL PCVAD HERD John Waddell, DVM, MBA
      • Determine the impact of one-dose of Ingelvac CircoFLEX® on growth performance of pigs in a “subclinical” PCVAD population
      • Determine if population weight distribution can be affected by immunization against PCV2
      Objectives
      • Source farm is PRRSV naïve with routine monitoring
      • 600 weaned pigs ( 21 days of age) were tagged, weighed and randomized at weaning by weight and sex
      • 300 vaccinates / 300 controls
      • Pigs were commingled within pens throughout the study
      • Individual body weights were taken at day 0 , day 35 , and day 119
      • Cull pigs were defined as weighing less than 180 lbs on day 119
      Material and Method
    2.  
      • Source farm is PRRSV naïve with routine monitoring
      • 600 weaned pigs ( 21 days of age) were tagged, weighed and randomized at weaning by weight and sex
      • 300 vaccinates / 300 controls
      • Pigs were commingled within pens throughout the study
      • Individual body weights were taken at day 0 , day 35 , and day 119
      • Cull pigs were defined as weighing less than 180 lbs on day 119
      Material and Method
    3.  
      • Source farm is PRRSV naïve with routine monitoring
      • 600 weaned pigs ( 21 days of age) were tagged, weighed and randomized at weaning by weight and sex
      • 300 vaccinates / 300 controls
      • Pigs were commingled within pens throughout the study
      • Individual body weights were taken at day 0 , day 35 , and day 119
      • Cull pigs were defined as weighing less than 180 lbs on day 119
      Material and Method
    4.  
    5. Serology
    6. Serology
      • 93 randomly selected pigs
        • Controlled for treatment group and sex
      • Six serial blood collection throughout study
      • PCV2, PRRS, Salmonella, Lawsonia and Mycoplasma
    7. Results
    8. 1 Cull rate based on animals weighing less than 180 lbs on d119 Mortality and cull rate (Fisher's Exact Test) Results Variable Vaccinates Controls P-value Mortality Rate (%) 3.01 3.86 0.22 Cull Rate¹ (%) 1.34 6.69 0.001
    9. 1 Probability of a greater F-statistic Least square means for performance data ab Within a row, means without a common superscript letter differ (Student's t, P≤ 0.05) Results Variable Vaccinates Controls P-Value¹ Day 0 weight (lbs) 16.17 16.17 0.97 Day 35 weight (lbs) 50.83 50.79 0.94 Day 119 weight (lbs) 227.25 a 220.86 b 0.0005 Day 0-35 ADG (lbs) 0.99 0.99 0.91 Day 36-119 ADG (lbs) 2.10 a 2.02 b <0.0001 Day 0-119 ADG (lbs) 1.77 a 1.72 b 0.0006 Day 0-119 wt gain (lbs) 210.71 a 204.38 b 0.0006
    10. Results Coefficient of Variation (CV) = 10.64(Vaccinated); 12.93 (Non-Vaccinated)
    11. PCV2 Quantitative PCR a a a b b b Log Titer Weeks Post-Vaccination
      • The one dose PCV2 vaccine significantly increased growth rate (weight gain and ADG) in a population of high health pigs which do not meet the case definition of (clinical) PCVAD.
      • Culling rate was significantly reduced by vaccination.
      • Consistent with a diagnosis of subclinical PCVAD, the mortality rate did not significantly differ and this was not a primary complaint of the producer.
      Conclusions
      • The right shift of weights and narrowing of weight range distribution for the vaccinated group of pigs illustrates the biologic and implied economic benefit of immunization.
      Conclusions
    SlideShare Zeitgeist 2009

    + John BlueJohn Blue Nominate

    custom

    241 views, 0 favs, 0 embeds more stats

    Experiences with the subclinical control of PCV2.

    more

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 241
      • 241 on SlideShare
      • 0 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 0
    Most viewed embeds

    more

    All embeds

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories